 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- PRS-344 / Pieris Pharmaceuticals
Trial completion date, Trial primary completion date, Metastases: Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Sep 22, 2024
P1, N=3, Terminated, Sponsor: Institut de Recherches Internationales Servier
Trial completion date: Jul 2023 --> Jun 2024 | Trial primary completion date: Jul 2023 --> Jun 2024
- PRS-344 / Pieris Pharmaceuticals
Enrollment change, Trial termination, Metastases: Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Aug 15, 2024
P1, N=3, Terminated, Sponsor: Institut de Recherches Internationales Servier
Trial completion date: Jul 2023 --> Jun 2024 | Trial primary completion date: Jul 2023 --> Jun 2024 N=33 --> 3 | Recruiting --> Terminated; Sponsor decision
- ||| PRS-344 / Pieris Pharmaceuticals
Enrollment change: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors (clinicaltrials.gov) - Aug 14, 2024
P1/2, N=45, Active, not recruiting, Sponsor: Servier Bio-Innovation LLC
N=33 --> 3 | Recruiting --> Terminated; Sponsor decision N=130 --> 45
- || PRS-344 / Pieris Pharmaceuticals
Enrollment closed, Trial primary completion date: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors (clinicaltrials.gov) - Jul 29, 2024
P1/2, N=130, Active, not recruiting, Sponsor: Servier Bio-Innovation LLC
N=130 --> 45 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2027 --> Dec 2025
- | PRS-344 / Pieris Pharmaceuticals
Trial completion date, Trial primary completion date, Metastases: Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Mar 25, 2024
P1, N=33, Recruiting, Sponsor: Institut de Recherches Internationales Servier
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2027 --> Dec 2025 Trial completion date: Oct 2023 --> Sep 2025 | Trial primary completion date: Oct 2023 --> Jun 2025
- || PRS-344 / Pieris Pharmaceuticals
Trial completion date, Trial primary completion date: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors (clinicaltrials.gov) - Dec 19, 2023
P1/2, N=130, Recruiting, Sponsor: Servier Bio-Innovation LLC
Trial completion date: Oct 2023 --> Sep 2025 | Trial primary completion date: Oct 2023 --> Jun 2025 Trial completion date: Nov 2024 --> Oct 2027 | Trial primary completion date: Nov 2024 --> Oct 2027
- PRS-344 / Pieris Pharmaceuticals, Servier
Assessment of target-mediated biodistribution of an 89Zr labeled PD-L1/4-1BB bispecific Mabcalin protein (Section 3; Poster Board #4) - Mar 14, 2023 - Abstract #AACR2023AACR_6573;
89Zr-Atezo-J10 specific accumulation in PD-L1 expressing tumors is due to both PD-L1 and 4-1BB binding and is higher than with PD-L1 and 4-1BB mono-targeting. This preclinical study supports the clinical evaluation of 89Zr-PRS-344/S095012
- || PRS-344 / Pieris Pharmaceuticals
Enrollment open, Metastases: Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Dec 13, 2022
P1, N=33, Recruiting, Sponsor: Institut de Recherches Internationales Servier
This preclinical study supports the clinical evaluation of 89Zr-PRS-344/S095012 Not yet recruiting --> Recruiting
- || PRS-344 / Pieris Pharmaceuticals
New P1 trial, Metastases: Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Dec 6, 2022
P1, N=33, Not yet recruiting, Sponsor: Institut de Recherches Internationales Servier
- | PRS-344 / Pieris Pharmaceuticals, Servier
Journal, PD(L)-1 Biomarker, IO biomarker: The PD-L1/4-1BB bispecific Antibody-Anticalin fusion protein PRS-344/S095012 elicits strong T-cell stimulation in a tumor-localized manner. (Pubmed Central) - Aug 6, 2022
Not yet recruiting --> Recruiting The PD-L1/4-1BB bispecific PRS-344/S095012 efficiently combines checkpoint blockade with a tumor-localized 4-1BB mediated stimulation burst to antigen-specific T cells, more potent than the combination of mAbs, supporting the advancement of PRS-344/S095012 towards clinical development.
- | cinrebafusp alfa (PRS-343) / Pieris Pharmaceuticals, Servier, elarekibep (PRS-060) / Pieris Pharmaceuticals, AstraZeneca, PRS-344 / Pieris Pharmaceuticals, Servier
Journal: Anticalin®-based therapeutics: Expanding new frontiers in drug development. (Pubmed Central) - Jul 9, 2022
Cinrebafusp alfa and PRS-344/S095012 antibody-Anticalin bispecific proteins were designed to reduce potential systemic toxicity by localizing the activity to the tumor, and are currently in clinical development in immuno-oncology. Furthermore, the ease in generating bi- and multispecifics as well as the small and stable structure prompted the investigation of Anticalin proteins for the CAR T space, opening additional potential treatment options based on Anticalin protein therapies.
- ||| PRS-344 / Pieris Pharmaceuticals
Enrollment change: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors (clinicaltrials.gov) - May 18, 2022
P1/2, N=130, Recruiting, Sponsor: Pieris Pharmaceuticals, Inc.
Furthermore, the ease in generating bi- and multispecifics as well as the small and stable structure prompted the investigation of Anticalin proteins for the CAR T space, opening additional potential treatment options based on Anticalin protein therapies. N=45 --> 130
- PRS-344 / Pieris Pharmaceuticals, Servier
The PD-L1/4-1BB bispecific antibody-Anticalin fusion protein PRS-344/S095012 elicits strong T-cell stimulation in a tumor-localized manner () - May 9, 2022 - Abstract #CIMT2022CIMT_155;
We finally provide evidence that soluble 4-1BB is a potential biomarker of 4-1BB agonism in patients. Taken together our preclinical data outline proof of concept for the functionality of PRS-344/S095012 and support further clinical development of this drug candidate.
- PRS-344 / Pieris Pharmaceuticals, Servier
Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors (Section 35) - Mar 9, 2022 - Abstract #AACR2022AACR_5902;
P1/2
Phase 2 is an expansion with primary objective of anti-tumor activity. First patient was dosed in November 2021 and the study is planned to enroll at sites in Belgium, Spain and Australia.
- | PRS-344 / Pieris Pharmaceuticals, Servier
Journal, PD(L)-1 Biomarker, IO biomarker: The PD-L1/4-1BB bispecific Antibody-Anticalin fusion protein PRS-344/S095012 elicits strong T-cell stimulation in a tumor-localized manner. (Pubmed Central) - Feb 23, 2022
First patient was dosed in November 2021 and the study is planned to enroll at sites in Belgium, Spain and Australia. The PD-L1/4-1BB bispecific PRS-344/S095012 efficiently combines checkpoint blockade with a tumor-localized 4-1BB mediated stimulation burst to antigen-specific T cells, more potent than the combination of mAbs, supporting the advancement of PRS-344/S095012 towards clinical development.
- || PRS-344 / Pieris Pharmaceuticals
New P1/2 trial: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors (clinicaltrials.gov) - Dec 15, 2021
P1/2, N=45, Recruiting, Sponsor: Pieris Pharmaceuticals, Inc.
- PRS-344 / Pieris Pharmaceuticals, Servier
[VIRTUAL] Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1 / 4-1BB bispecific compound for tumor localized activation of the immune system (eTalks Room) - May 11, 2021 - Abstract #CIMT2021CIMT_71;
Furthermore, dual mechanism of action combining PD-L1-dependent 4-1BB agonist activity with simultaneous PD-1/PD-L1 pathway blockade provides an additional therapeutic benefit in preclinical models. Taken together our data outlines proof of concept of PRS-344/S095012 and supports further development.
- ||| PRS-344 / Pieris Pharmaceuticals, Servier
$PIRS Servier S095012 ako partnered #PRS-344 at #AACR21 https://t.co/XbYLzXvyiH (Twitter) - Apr 9, 2021
- |||| cinrebafusp alfa (PRS-343) / Pieris Pharmaceuticals, PRS-060 / Pieris Pharmaceuticals, AstraZeneca, PRS-344 / Pieris Pharmaceuticals, Servier
P2a data: Excited for the AZD1402/PRS-060 phase 2a initiation, equity investment by @AstraZeneca announced today, and the upcoming oral and poster presentations for @PierisPharma's HER-2- and PD-L1- targeting 4-1BB bispecifics, cinrebafusp alfa (PRS-343) and PRS-344 at @AACR 2021. (Twitter) - Mar 30, 2021
- PRS-344 / Pieris Pharmaceuticals, Servier
[VIRTUAL] Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1 / 4-1BB bispecific compound for tumor localized activation of the immune system () - Mar 11, 2021 - Abstract #AACR2021AACR_3463;
Furthermore, dual mechanism of action combining PD-L1-dependent 4-1BB agonist activity with simultaneous PD-1/PD-L1 pathway blockade provides an additional therapeutic benefit in preclinical models. Taken together our in vitro and in vivo data outlines proof of concept functionality of PRS-344/S095012 and supports further development of this promising compound.
- || PRS-344 / Pieris Pharmaceuticals, Inc., Servier
$PIRS Provides Update on Servier Collaboration. Servier has decided to focus on continued and accelerated development of the two most advanced programs, including PRS-344/S095012, and to discontinue development of the two earlier-stage programs in the collaboration. (Twitter) - Mar 24, 2020
- PRS-344 / Pieris Pharmaceuticals, Inc., Servier
Beyond mAbs : PRS-344/S095012, a 4-1BB / PDL1 bispecific compound for tumor-localized immune cell Activation () - Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_149;
Overall, our efficacy data provide proof of concept of PRS-344/S095012. Additionally, very good developability of PRS-344/S095012 supports IND-enabling studies of this promising compound.